The letters, many of which were already available online, detail why the regulators initially declined to approve some drugs.

In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting ...

In April 2025, the US Food and Drug Administration (FDA) published a roadmap for leveraging new approach methodologies (NAMs), including in silico approaches such as artificial intelligence (AI), to ...

Top regulators like the US FDA and EMA are fast-tracking more Chinese drugs, granting priority review and breakthrough ...

The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way from their ...

Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology ...

A large-scale bibliometric analysis maps global research on hydrogels as next-generation drug delivery systems for cancer ...

GeneDx leverages a vast rare disease database and advanced genomic testing, offering superior insights. Read why I am bullish about WGS stock.

The Global Bioinformatics Market is expected to grow at a rate of 13-14% by 2029. The rising government initiatives and funding for genomics research, increasing applications of bioinformatics in drug ...

NIH budget cuts are threatening key medical research programs, shrinking training grants, and leaving young researchers ...

Using an AI-driven drug discovery process, the drug known as vorinostat was identified as a promising treatment for Rett ...